Clinical trial NCT03026803: A Study of Oxaliplatin and Capecitabine in Unresectable Metastatic Hepatocellular Cancer
Official title: A Phase II Study of Oxaliplatin and Capecitabine in Unresectable Metastatic Hepatocellular Cancer
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Liver Cancer
Hepatocellular Cancer
Lead sponsor: City of Hope Medical Center
Sponsor class: OTHER
Collaborators: name: Sanofi
First posted: 2017-01-20
Enrollment: 4
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This phase II trial is studying how well giving oxaliplatin and capecitabine together works in treating patients with liver cancer.

Detailed description: Drugs used in chemotherapy, such as oxaliplatin and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving these drugs together may kill more tumor cells.

Eligibility criteria: Inclusion Criteria:

* Patients must have histologically confirmed hepatocellular carcinoma which is recurrent, metastatic or unresectable.
* Patients may have up to two prior chemotherapy regimes. In addition, they may have had previous radiation, chemoembolization, and/or alcohol injections.
* Patients must have measurable disease, defined as lesions that can be accurately measured in at least one dimension (longest diameter to be recorded) as ≥20 mm with conventional techniques or as ≥10 mm with spiral CT scan, and which has clearly progressed during the observation interval prior to participation in this study. Pleural effusions and ascites will not be considered measurable, but may be present in addition to the measurable lesion(s).
* Karnofsky performance status \> 70%.
* Patients should have an expected survival of at least 2 months.
* Leukocytes \>3,000/µl
* Absolute neutrophil count \>1,500/µl
* Platelets \>50,000/µl
* Total bilirubin \< 3.0 g/dl
* AST (aspartate aminotransferase) (serum glutamic oxaloacetic transaminase(SGOT)/ALT (alanine aminotransferase) (serum glutamic pyruvic transaminase)(SGPT) \< 5 times institutional upper limit of normal
* Creatinine \< 2.0 OR measured or calculated creatinine clearance \>60 mL/min for patients with creatinine levels above institutional normal
* Brain metastasis is not an exclusion, however, patients are only eligible if they have had successful control of the brain tumor(s) by surgery or stereotactic RT.
* Patients with no evidence of clinically significant neuropathy.
* All prior therapy must have been completed at least 4 weeks prior to the patient's entry on this trial.
* Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
* Breastfeeding should be discontinued if the mother is treated with oxaliplatin.
* Subjects with chronic hepatitis B or C may be undergoing treatment with α interferon and/or ribavirin, as long as they meet the other criteria for entry on to this study.
* Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

* Patients have prior oxaliplatin or xeloda treatment or undergoing therapy with other investigational agents.
* History of allergy to platinum compounds or to antiemetics appropriate for administration in conjunction with protocol-directed chemotherapy.
* Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, or unstable angina pectoris, or cardiac arrhythmia.
* HIV-positive patients receiving anti-retroviral therapy (HAART) are excluded from the study because of possible pharmacokinetic interactions.
* Patients with a diagnosis of pulmonary fibrosis or a pulmonary interstitial process.
* Patients unable to swallow capecitabine will be excluded from this study.

Primary outcomes:
measure: Response Rate
timeFrame: Up to 2 years
Secondary outcomes:
Other outcomes:
Locations:
city: Duarte
country: United States
facility: City of Hope Medical Center
state: California
Study officials:
affiliation: City of Hope Medical Center
name: Yun Yen, MD
role: PRINCIPAL_INVESTIGATOR
References: